{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-273358","form_type":"8-K","ticker":"CERO","cik":"0001870404","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2022-10-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.860516+00:00","generated_at":"2026-06-22T21:57:13.009052+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Phoenix Biotech SPAC to merge with Intrinsic Medicine in all-stock deal","bullets":["Consideration: 13.6M shares of Class A common stock to Intrinsic equity holders.","Intrinsic is a preclinical-stage therapeutics company using synthetic biology to develop human milk oligosaccharide medicines.","Closing requires at least $15M available cash (trust + PIPE), Nasdaq listing, and stockholder approvals.","Sponsor and key Intrinsic stockholders agree to vote in favor; lock-up 180 days or $12.50 price trigger.","Post-combination company to be led by executives Martinez, Ferrone, Chuang, and Crawford."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-273358","json":"https://secwatch.observer/filing/0001193125-22-273358.json","markdown":"https://secwatch.observer/filing/0001193125-22-273358.md","text":"https://secwatch.observer/filing/0001193125-22-273358.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1870404/000119312522273358/0001193125-22-273358-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1870404/000119312522273358/d417140d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T21:57:13.009052+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c4ccc48aad2e8329653a4b91255239768750c8ce","claim":"CERO THERAPEUTICS HOLDINGS, INC. entered into Business Combination Agreement with OM Merger Sub, Inc., Intrinsic Medicine, Inc. (effective 2022-10-30).","evidence_excerpt":"On October 30, 2022, Phoenix Biotech Acquisition Corp., a Delaware corporation (the “ Company ”), entered into a business combination agreement (the “ Business Combination Agreement ”) by and among the Company, OM Merger Sub, Inc., a Delaware corporation (“ Merger Sub ”), and Intrinsic Medicine, Inc., a Delaware corporation (“ Intrinsic ”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1870404/000119312522273358/0001193125-22-273358-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"merger"},{"label":"Counterparty","value":"OM Merger Sub, Inc., Intrinsic Medicine, Inc."},{"label":"Effective","value":"2022-10-30"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}